Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licence

Novartis building

Novartis says Afinitor fails liver cancer trial

Halts plans to file for approval in new indication

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

- PMLiVE

Roche loses Herceptin patents in India

Government says pharma company did not follow correct filing procedure

Bayer symbol

Bayer to research cancer immunotherapies with Compugen

Will develop drugs that boost response of body’s immune system to tumours

- PMLiVE

GSK loses patent on Tykerb in India

Cuts period of exclusivity by two years

Roche - Basel

Roche cuts cost of drug to prevent blindness in HIV patients

Will improve access to Valcyte in developing nations

- PMLiVE

Merck profit slides as generics continue to bite

Singulair, Maxalt, Cozaar and Clarinex sales all affected

- PMLiVE

Pfizer separates branded and generic divisions

Follows spin out of animal health and nutrition

Bristol-Myers Squibb (BMS) building

BMS signs 10-year biologic manufacturing deal with Samsung

Agreement covers one of the pharma company's antibody cancer drugs

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

Roche - Basel

New cancer drugs help drive Roche in first half

Perjeta, Kadcyla and Zelboraf support company growth

Roche - Basel

Roche antibody tops Rituxan in blood cancer CLL

Obinutuzumab on course for leukaemia approval by year-end

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links